genXtraits Inc. has announced that it has entered into an agreement with Pairwise to deploy its Fulcrum editing tools to ...
This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
Science and technology have advanced exponentially and show no signs of slowing down. But technological breakthroughs require ...
The Evo can design DNA sequences to manipulate cell functions, create new genes, and even develop an entirely new CRISPR gene ...
The Next Big Disruptor?" report has been added to ResearchAndMarkets.com's offering.Once confined to laboratories, engineered bacteria have evolved from simple research tools into powerful industrial ...
In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle ...
Tuerkcan covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Crispr Therapeutics AG, and Terns Pharmaceuticals. Currently, the analyst consensus on Benitec Biopharma ...
Dr. Shyam Sundar Nandi from the National Institute of Virology has created a rapid mpox testing kit that delivers results in ...
The recent updates from the Phase 1 trials of NTLA-2001, an in-vivo CRISPR/Cas9 based therapy, have shown encouraging results in ATTR-CM and ATTR-PN conditions. These findings, presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback